| |
# of studies
|
SMD
|
LL
|
UL
|
p-value
|
|
Control
| | | | | |
|
Nonstandard
|
3
|
0.23
|
−0.41
|
0.88
|
0.8
|
|
Standard
|
4
|
0.37
|
−0.45
|
1.19
| |
|
Overall
|
7
|
0.29
|
−0.22
|
0.8
| |
|
Proctor present for control?
|
|
No
|
1
|
0.57
|
0.17
|
0.97
|
0.65
|
|
Yes
|
5
|
0.37
|
-0.44
|
1.17
| |
|
Proctor present for intervention?
|
|
No
|
2
|
0.51
|
0.14
|
0.88
|
0.85
|
|
Yes
|
4
|
0.41
|
-0.52
|
1.34
| |
|
Subjects
| | | | | |
|
Patients
|
4
|
0.69
|
0.14
|
1.25
|
0.33
|
|
Volunteers
|
1
|
0.16
|
-0.76
|
1.09
| |
|
Setting
| | | | | |
|
Real
|
4
|
0.12
|
-0.65
|
0.89
|
0.25
|
|
Simulated
|
3
|
0.64
|
0.22
|
1.06
| |
|
Enhanced consent form vs. control
|
| |
# of studies
|
SMD
|
LL
|
UL
|
p-value
|
|
Control
| | | | | |
|
Nonstandard
|
3
|
2.33
|
0.01
|
4.66
|
0.49
|
|
Standard
|
8
|
1.47
|
0.7
|
2.23
| |
|
Proctor present in both groups?
|
|
No
|
7
|
2.6
|
1.33
|
3.88
|
0.01
|
|
Yes
|
2
|
0.33
|
-0.43
|
1.09
| |
|
Subjects
| | | | | |
|
Patients
|
4
|
2.56
|
0.69
|
4.44
|
0.59
|
|
Volunteers
|
5
|
1.94
|
0.66
|
3.23
| |
|
Setting
| | | | | |
|
Real
|
3
|
0.57
|
-0.06
|
1.19
|
0.01
|
|
Simulated
|
8
|
2.23
|
1.19
|
3.28
| |
|
Extended discussion vs. control
|
| |
# of studies
|
SMD
|
LL
|
UL
|
p-value
|
|
Proctor present in control group?
|
|
No
|
3
|
1.31
|
0.33
|
2.29
|
0.19
|
|
Yes
|
1
|
0.63
|
0.33
|
0.93
| |
|
Subjects
| | | | | |
|
Patients
|
2
|
1.33
|
-0.07
|
2.74
|
0.53
|
|
Volunteers
|
2
|
0.83
|
0.19
|
1.47
| |
|
Setting
| | | | | |
|
Real
|
1
|
2.06
|
1.61
|
2.52
|
0.01
|
|
Simulated
|
3
|
0.66
|
0.39
|
0.93
| |
